
Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation
Keywords: سیکلودکسترین; Erlotinib; Tyrosine kinase inhibitor; Pancreatic cancer; Cyclodextrin; Sulfobutyl ether β-cyclodextrin; Solubility enhancement; Erlotinib hydrocholide (PubChem CID: 176871); α-Cyclodextrin (PubChem CID: 444913); β-Cyclodextrin (PubChem CID: 444041); γ